Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia

Abstract

Objective:To conduct a cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) as an instrument to evaluate the perception of symptoms, functional limitation, and health-related quality of life (HRQoL) in subjects diagnosed with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) in Colombia. Methods:The adaptation process involved 3 phases: translation, cognitive debriefing interviews, and a validation survey. To evaluate the psychometric properties, we recruited individuals ≥ 18 years of age who had been diagnosed with PAH or CTEPH to take part in the latter two stages of the adaptation process. All individuals were being followed on an outpatient basis by the pulmonary hypertension programs at Hospital Universitario San Ignacio, Fundación Clínica Shaio,and Clínicos IPS, all located in the city of Bogotá, Colombia. Results:A Spanish-language version of the CAMPHOR was developed for use in Colombia. The internal consistency was excellent for the symptoms, functioning, and quality of life scales (Cronbach’s alpha coefficients of 0.92, 0.87, and 0.93, respectively). Test-retest reliability was above 0.70. The evaluation of the convergent validity and known group validity of the CAMPHOR scales confirmed that there were moderate and strong correlations with the related constructs of the Medical Outcomes Study 36-item Short-Form Health Survey, version 2, as well as showing their capacity to discriminate disease severity. Conclusions:The Spanish-language version of the CAMPHOR developed for use in Colombia was the result of a translation and cultural adaptation process that allows us to consider it equivalent to the original version, having shown good psychometric properties in the study sample. Therefore, its use to assess the impact of interventions on the HRQoL of patients with PAH or CTEPH is recommended, in research and clinical practice.

Cultural adaptation of the Polish version of the PAH-SYMPACT questionnaire (PL)

“…with each other in all domains in a statistically signi cant manner (p < 0.05) [7,23]. However, Ganderton et al [8] noted that in clinical trials, the SF-36 has been shown to respond only moderately to changes following the application of some intervention in patients with PAH.…”

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension

“…CAMPHOR has also received criticism for being more time intensive than other available pulmonary hypertension QOL measures, however remains the most validated with adaption for use in, but not limited to, the: United States, 39 Australia/New Zealand, 40 Portugal, 41 Germany, 42 Netherlands, 43 Poland, 44 Brazil, 45 Croatia, 46 French/English Canada 47 and Columbia. 48 This provides plentiful opportunity for the external validation of MCID estimates to assess their robustness which is unafforded by other measures at present. Moreover, CAMPHOR is the only clinically utilised measure inclusive of a global assessment of health.…”

“…Poland [44], Brazil [45], Croatia [46], French/English Canada [47] and Columbia [48]. This provides plentiful opportunity for the external validation of MCID estimates to assess their robustness which is unafforded by other measures at present.…”

Adaptation and validation of the quality of life assessment of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for Brazil

“…The measure was developed and validated in a unique PH reference center in United Kingdom and has been adapted for use in many countries, providing a valuable tool to reflect the actual patient experience in each country [13][14][15][16][17][18][19][20]. However, a validated version of the CAMPHOR for use in Brazil has been previously unavailable.…”